Stockscreener 앱 받기
16.97
4.11%
0.67
시간 외 거래:
17.00
0.03
+0.18%
전일 마감가:
$16.30
열려 있는:
$16.51
하루 거래량:
1.68M
Relative Volume:
1.45
시가총액:
$1.75B
수익:
$71.78M
순이익/손실:
$-295.28M
주가수익비율:
-5.3708
EPS:
-3.1597
순현금흐름:
$-271.85M
1주 성능:
+8.78%
1개월 성능:
+12.83%
6개월 성능:
+63.96%
1년 성능:
+72.81%
1일 변동 폭
$16.36
$17.11
1주일 범위
$15.47
$17.11
52주 변동 폭
$8.195
$22.50
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
16.97 | 1.69B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Does Nurix Therapeutics (NRIX) have the potential to rally 85.84% as Wall Street analysts expect? - MSN
Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst - MarketBeat
NRIX: Lead BTK degrader enters phase III for CLL, with strong efficacy and robust financial runway - TradingView — Track All Markets
NRIX: Lead BTK degrader enters phase III in CLL, with strong efficacy and broad pipeline momentum - TradingView — Track All Markets
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Weakness - Sahm
(NRIX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative? - Yahoo Finance
Does Wall Street Predict an 85.84% Surge for Nurix Therapeutics (NRIX)? - Bitget
Nurix Therapeutics, Inc. (NRIX) reports Q1 loss, lags revenue estimates - MSN
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect? - Yahoo Finance
Growth Report: Can Nurix Therapeutics Inc sustain its profitabilityWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
HC Wainwright Reaffirms Buy Rating on NRIX with $32 Target | NRI - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story - Sahm
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView — Track All Markets
Portfolio Recap: Is Nurix Therapeutics Inc undervalued by DCF analysis2026 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
NRIX: Wells Fargo Adjusts Price Target while Maintaining Overwei - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $28.00 by Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo cuts Nurix stock price target on CLL trial timing - Investing.com
Nurix Therapeutics (NRIX) Heavy Q1 Net Loss Reinforces Bearish Narrative On Profitability - Sahm
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Break - GuruFocus
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Breakdown - GuruFocus
Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment - mexc.co
NRIX: Needham Reiterates Buy Rating with Target Price of $26.00 - GuruFocus
Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress - CoinCentral
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL - TipRanks
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Bitget
Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results - AlphaStreet
Nurix Therapeutics stocks rise 3% despite Q1 miss - Investing.com
Nurix Therapeutics stocks rise 3% despite Q1 miss By Investing.com - Investing.com South Africa
Nurix Therapeutics, Inc. Q1 2026 Financial Results: Continued R&D Investment, Collaboration Revenue, and Key Risk Factors Highlighted in 10-Q Filing - Minichart
Nurix Therapeutics (NRIX) Q1 FY2026 Earnings: EPS -$0.79 (Miss v - GuruFocus
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2026 - marketscreener.com
Nurix Therapeutics Reports Q1 2026 Financial Results and Corporate Update - Minichart
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
NRIX Reports Lower Q1 Revenue; Focuses on Key Medical Developmen - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix Therapeutics Fiscal Q1 Loss Widens, Revenue Falls - marketscreener.com
[10-Q] Nurix Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics Posts Fiscal Q1 Loss $0.79 a Share, vs. FactSet Est of $0.76 Loss - marketscreener.com
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, vs. FactSet Est of $14.3M - marketscreener.com
Nurix Therapeutics 3Q 2026: Revenue $6.25M, EPS $(0.79) — 10-Q Summary - TradingView — Track All Markets
Nurix Therapeutics Q1 loss widens on higher costs - TradingView
NRIX: Q1 2026 saw pipeline progress, higher R&D costs, and a strong cash position amid lower revenue - TradingView — Track All Markets
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):